Pulmonary Arterial Hypertension

Pulmonary Hypertension (PH) is a serious and progressive group of conditions with various causes and no cure.^[1]2 There are five groups of PH, as defined by the World Health Organization (WHO), and they are characterized by increased blood pressure in the lungs.^[1]

Janssen’s focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.^[1]

In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. We have made PH a ‘therapeutic area of focus’ and are committed to maintaining and building on the leadership position that Actelion has built in this important disease area.

At Janssen, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

We want to use our full range of resources to tackle PH. From investment in research and development to innovation in medical devices and diagnostics, our commitment to building an innovative drug development pipeline is real. We're focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.